CRVS - Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01 March, 10 2022 04:14 PM Corvus Pharmaceuticals Inc. Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q4 GAAP EPS of -$0.20 misses by $0.01. Q4 Cash and cash equivalents $69.45M For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01